Nobivac L4
Vaccine to prevent Leptospira infections in dogs
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Nobivac L4
|
Agency product number |
EMEA/V/C/002010
|
Active substance |
|
International non-proprietary name (INN) or common name |
Vaccine to prevent Leptospira infections in dogs
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07AB01
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
6
|
Date of issue of marketing authorisation valid throughout the European Union |
16/07/2012
|
Contact address |
Wim de Körverstraat 35
5831 AN Boxmeer The Netherlands |
Product information
07/10/2021 Nobivac L4 - EMEA/V/C/002010 - WS/2058/0012
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of dogs against:
- Leptospira interrogans serogroup Canicola serovar Canicola to reduce infection and urinary excretion;
- L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion;
- L. interrogans serogroup Australis serovar Bratislava to reduce infection;
- L. kirschneri serogroup Grippotyphosa serovar Bananal / Lianguang to reduce infection and urinary excretion.